GPBAR1 and Hepatic steatosis: These include alterations in enterohepatic bile acid signaling mediated via farnesoid X receptor and its downstream targets fibroblast growth factor 15 as well as through TGR5, which produce favorable metabolic shifts in glucose and lipid metabolism and amelioration of hepatic steatosis (40, 41).